Mustang Bio (MBIO) said Thursday that MB-108, an oncolytic virus currently undergoing phase 1 clinical trial for malignant glioma treatment, has been granted orphan drug designation by the US Food and Drug Administration.
The designation provides MB-108 seven years of market exclusivity in the US for the treatment.
Mustang also said it plans to seek orphan drug designation from the FDA for MB-101, an investigational CAR-T cell therapy for malignant gliomas.
The company said its novel strategy is to combine MB-108 oncolytic virus with MB-101 CAR-T cell therapy to optimize clinical results. It said both MB-101 and MB-108 are well tolerated in patients with recurrent glioblastoma, a type of brain tumor.
Shares of Mustang Bio were up more than 3% in recent trading.
Price: 0.25, Change: +0.01, Percent Change: +3.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。